29 August 2019 - Pre-exposure prophylaxis (PrEP)—an HIV prevention intervention consisting of a daily drug cocktail, quarterly HIV/sexually transmitted disease screening, and laboratory monitoring—has repeatedly been shown to be safe, effective, and cost-effective. 

Although US guidelines have recommended PrEP for all high-risk individuals since 2014, fewer than 200,000 of the 1.2 million eligible Americans are enrolled in a PrEP program. 

The burden of inadequate coverage is borne disproportionately by the nation’s most vulnerable communities.

Read Health Affairs article